Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Boston MA, New York NY, Hackensack NJ,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 12+

Code: NCT05533697

Phase 1, Phase 2, Recruiting
Active & Responsive

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

for
Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Location: Greenville SC
Sponsor: University of South Carolina

Sex: Female

Age: 20+

Code: NCT06672497

Recruiting
Active & Responsive

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

for
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer,
Location: Hartford CT, New York NY, Englewood NJ, Florham Park NJ,
Sponsor: VM Oncology, LLC

Sex: All

Age: 18 - 70+

Code: NCT03556228

Phase 1, Phase 2, Recruiting
Active & Responsive

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

for
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer,
Location: New York NY
Sponsor: Deborah Doroshow

Sex: All

Age: 18+

Code: NCT04997993

Phase 1, Recruiting
Active & Responsive

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

for
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Location: Hackensack NJ, Washington D.C. DC
Sponsor: Georgetown University

Sex: Female

Age: 18+

Code: NCT05256745

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

for
Breast Cancer, Breast Neoplasm, Breast Tumor,
Location: New York NY, Hampton VA, Baltimore MD, Fairfax VA,
Sponsor: Proton Collaborative Group

Sex: Female

Age: 50+

Code: NCT01766297

Phase 2, Recruiting
Active & Responsive

Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study

for
Breast Cancer, Disability Physical, Heart Failure,
Location: Edmonton
Sponsor: University of Alberta

Sex: Female

Age: 60+

Code: NCT06595147

Recruiting
Active & Responsive

Protein Needs Study

for
Colorectal Cancer, Breast Cancer
Location: Edmonton
Sponsor: University of Alberta

Sex: All

Age: 45 - 70+

Code: NCT04144907

Recruiting
Active & Responsive

Activating Cancer Communities Through an Exercise Strategy for Survivors

for
Cancer
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: All

Age: 18+

Code: NCT03599843

Recruiting
Active & Responsive

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis,
Location: Boston MA, New Haven CT, New York NY,
Sponsor: Institut de Recherches Internationales Servier

Sex: All

Age: 18+

Code: NCT05786924

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

for
Metastatic Solid Tumors
Location: Boston MA, New York NY, Fairfax VA, Toronto, Tampa FL,
Sponsor: Erasca, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06983743

Phase 1, Recruiting
Active & Responsive

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Jacksonville FL, Tampa FL, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06353191

Recruiting
Active & Responsive

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

for
Breast Cancer Female
Location: Kansas City KS
Sponsor: University of Kansas Medical Center

Sex: Female

Age: 65+

Code: NCT07242118

Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

for
Early Stage Triple-Negative Breast Carcinoma,
Location: Jacksonville FL, Rochester MN, Phoenix AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06349642

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for
Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult,
Location: Boston MA, Hackensack NJ, Philadelphia PA, Fairfax VA,
Sponsor: NiKang Therapeutics, Inc.

Sex: All

Age: 19+

Code: NCT06586957

Phase 1, Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

for
HER2-positive Breast Cancer, Metastatic Cancer,
Location: Birmingham AL, Chicago IL, Orland Park IL, New Lenox IL,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: All

Age: 18+

Code: NCT05868226

Phase 1, Phase 2, Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 16+

Code: NCT05269381

Phase 1, Phase 2, Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

for
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma,
Location: Boston MA, New Haven CT, Buffalo NY, Tampa FL,
Sponsor: Simcha IL-18, Inc.

Sex: All

Age: 18+

Code: NCT04787042

Phase 1, Phase 2, Recruiting

Access to Genetic Testing in Underserved Patients With Cancer

for
Breast Carcinoma, Male Breast Carcinoma,
Location: Rochester NY, Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18+

Code: NCT06422455

Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for
Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer,
Location: Long Island City NY, Manhattan NY, Fairfax VA,
Sponsor: Accent Therapeutics

Sex: All

Age: 18+

Code: NCT06799065

Phase 1, Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial